// subscribe
The AI Validation Boundary: Extended Edition
The articles stay open. The full worked examples come here: complete validation walkthroughs for probabilistic AI systems in regulated drug development, too long for a post. Free. No fixed schedule; you’ll hear from me when one is ready.
NewVersion 5.0, November 2026 — now crosswalked to FDA’s credibility assessment framework and the draft EU/PIC/S Annexes 11 and 22.
Read House of AI Trust version 5.0 nowValidation assurance for probabilistic systems in regulated science.
Where reproducibility is bounded, the validated state is a moving target, and conventional CSV practices were not designed for the sources of risk these systems introduce.
Britt Biocomputing builds the validation evidence that holds anyway — the plans, risk assessments, supplier qualifications, and audit trails your QMS needs before an inspector asks for them. Grounded in published frameworks that operationalize the FDA seven-step credibility framework, ICH Q9(R1), and the GAMP® 5 / GAMP® AI Guide lineage.
What does validating and governing your AI use case actually return?
Describe your AI use case and plug in your own numbers. The estimate shows the risk that validation and governance take off the table, the time-to-value they unlock, and how quickly the investment pays back.
1Your use case
These choices set the risk profile and pre-fill sensible starting assumptions.
2The value it creates
What the AI is worth when it's running in production.
3Your team optional
The same investment returns less when the team delivering it hasn't validated probabilistic AI before. The controls catch less, the work takes longer, and go-live slips.
Capability adjustments (illustrative — edit to fit)
How much of the designed risk reduction each team actually delivers, how much internal effort it takes compared with an experienced team, and how many months of time-to-value are lost.
| Risk reduction achieved | Internal effort | Months lost | |
| Limited | % | % | |
| Some | % | % | |
| Established | % | % |
4Risk assumptions pre-filled · optional
Pre-filled from your step 1 choices. These are illustrative starting points, not industry benchmarks, so replace them with your own data where you have it.
Investment and control effectiveness
Your estimate
Updates as you type.
- Data unification: bringing the data the AI uses and produces into one traceable, governed source
- Ontology / meaning layer: shared definitions so inputs, outputs and controls mean the same thing across systems and teams
- Internal resource hours: QA, CSV, IT, data and business SME time
- External capabilities: specialized validation, governance and tooling support
- Training: for users, reviewers and the quality organization
Depending on the organization, external capabilities can reduce the internal resource hours needed, through better coordination and more efficient execution.
CloseWhere the return comes from
Each line in the estimate maps to a control you put in place.
How this estimate works
Avoided error cost = outputs × error rate × escape rate × cost per error × reduction from controls. Avoided regulatory exposure = probability × cost × reduction. Re-validation efficiency = updates × (full-regression cost − risk-based cost). Time-to-value = (months of delay avoided − months lost to team inexperience) × monthly value (counted once). Team capability scales the risk reductions and internal cost; external support closes part of the capability gap and cuts internal hours, at an added fee. "Value it unlocks" adds the productivity value itself, on the basis that a GxP use case can't go into production without validation. All defaults are illustrative and should be replaced with your organization's own figures. This is a planning estimate, not a financial forecast.
If any of these sound familiar, this is the work.
We put an LLM in front of deviation triage — and QA is asking what the validation package looks like.
There's a defensible answer. It starts with context of use, not with the model.
Our AI vendor passed SOC 2. Our auditor still wants supplier qualification evidence.
SOC 2 doesn't cover silent model changes or inherited validation. VALID Trust does.
The model is frozen. So why does the system keep behaving differently?
The failure modes live in the harness — prompts, retrieval, tools, guardrails. Those drift, and they're validatable.
Named artifacts.
- →Use case triage & gap assessmentsScoped to context of use, model, harness, and human-in-the-loop.
- →Risk assessmentsBuilt on a published failure-mode taxonomy, mapped to ICH Q9(R1).
- →Supplier qualification packagesAI vendor qualification under the VALID Trust methodology.
- →Traceability & capture-layer designSo every AI decision is inspectable after the fact.
- →Validation artifactsThe document your inspector actually reads.
Three ways to engage: fixed-fee exposure screens and prioritized risk assessments, scoped engagements that produce inspection-ready evidence, and a fractional AI quality lead for teams that need the role before they can hire for it.
Work is sized to the consequence of error and to the maturity of your current posture.
See the full services overview →An integrated body of work, applied to your system.
Every engagement runs on frameworks that are public and citable. Your auditor can read the methodology before they read your evidence.
House of AI Trust
Five-layer governance architectureThe umbrella framework for AI in regulated drug development: five layers, each resting on the one beneath it, with Security and Supplier Qualification running through all of them. It shows where each control belongs, and what has to be in place before validation can hold. The three frameworks below operate within or alongside the House.
L3 is where Britt Biocomputing operates: the Control Layer, where governance becomes evidence — context of use, risk tiering, evaluation design, acceptance criteria, human oversight, continuous monitoring, and change control.
Read the flagship guide →Probabilistic Validation Lifecycle
Seven-step execution modelAdapts the V-model to systems where reproducibility is bounded rather than absolute. Maps cleanly onto GAMP 5 lifecycle stages while extending them for probabilistic behavior, drift, and continuous verification.
Read →VALID Trust
Four-pillar supplier qualificationA framework for qualifying AI suppliers and inheriting validation evidence in regulated environments. Extends GAMP 5 supplier qualification into non-deterministic upstream components.
Read →Probabilistic Failure Mode Taxonomy
6 × 6 classification matrixA public framework for classifying probabilistic AI failures in GxP regulated drug development by both error type and origin, mapped against GAMP 5, ICH Q9(R1), and the FDA seven-step credibility framework.
Read →Unified Capture Layer (UCL)
Deterministic runtime evidence captureA deterministic infrastructure layer that captures the runtime data a probabilistic system needs for assurance evidence. Built for systems of model × harness × HITL/HOTL, within a defined context of use, that are capable of output variation.
Coming soonLatest writing
Your Supplier's SOC 2 Doesn't Cover the Model
In a probabilistic system, a poisoned input and an ordinary error can look the same in the record, so security becomes a validation question. Which evidence a sponsor can inherit from the foundation model provider, cloud host, and vendor, and what it has to generate itself.
Agentic Validation, Operationally
Agentic design doesn't move the validation boundary. It grows the harness. The Probabilistic Validation Lifecycle carried through all seven steps for agents, with acceptance criteria layered from zero-tolerance invariants to outcome-level bounds, and the single invariant that would have caught an OOS error on day one instead of day seven.
The Data Boundary Inside the House
A misclassified deviation gets retrieved as precedent, passes human review, and re-enters the record as approved GMP data, ready to be retrieved again. Why data governance covers capture but not coupling, and where inbound data and re-entry cross the validation boundary.
Coherence ≠ Compliance: The Capability Paradox, 10 Months Later
As models grow more fluent, their errors get harder to see. A ledger of what's shipped since December, why agentic structure compounds error at every step, and why reading an SOP doesn't qualify the person reviewing the output.
The Inheritance Boundary Inside the House
How does a manufacturer show that layered AI controls produce reliable output? By knowing which evidence it can inherit from the supplier and which it must own, floor by floor of the House, walked through with a deviation intake triage assistant.
The Validation Boundary Inside the House
If a probabilistic system is CoU × model × harness × HITL, the inventory unit is the system, risk is determined per system, and acceptance criteria are domain judgments, not just statistical ones. Revisiting AI governance (Layer 2) and domain expertise (Layer 4) through that boundary.
Thirty minutes to find out whether this is your problem.
A scoping call is free and specific: what you've deployed, what your QA function is asking for, and what the evidence gap actually is.
Book a scoping call Or see the full services overview →